Harnessing nutrient scarcity for enhanced CAR-T-cell potency and safety in solid tumors.

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Chimeric antigen receptor (CAR)-T-cell therapy shows promise but faces challenges in solid tumors, including toxicity and T-cell dysfunction in the tumor microenvironment.
• Metabolic stress, particularly amino acid scarcity, impairs T-cell function within tumors.
• The GCN2-ATF4 pathway is critical for T-cell metabolic adaptation and function under stress.

Purpose of the Study:

• To develop a novel strategy to enhance CAR-T-cell therapy for solid tumors by targeting the GCN2-ATF4 pathway.
• To create an inducible CAR expression system regulated by amino acid availability within the tumor microenvironment.

Main Methods:

• Engineered CAR-T cells with an amino acid-dependent inducible promoter to control CAR expression.
• Utilized the GCN2-ATF4 axis for pathophysiological regulation of CAR expression.
• Evaluated the system's efficacy and safety in vitro and in murine xenograft models.

Main Results:

• The inducible system successfully restricted CAR expression to the tumor site under conditions of amino acid scarcity.
• Demonstrated enhanced safety by minimizing off-tumor CAR-T-cell activity.
• Showed improved CAR-T-cell fitness and reduced exhaustion within the tumor microenvironment.

Conclusions:

• The developed inducible CAR expression system effectively targets the GCN2-ATF4 axis for enhanced CAR-T-cell therapy in solid tumors.
• This strategy addresses key limitations of current CAR-T-cell therapies, improving safety and efficacy.
• Paves the way for innovative therapeutic strategies against solid malignancies.